Utilizing mast cells in a positive manner to overcome inflammatory and allergic diseases

Zhongwei Zhang1, Peter B. Ernst2,3,4, Hiroshi Kiyono4,5,6,7,8,9,10 and Yosuke Kurashima1,6,9,10,11,12*

1Department of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan, 2Division of Comparative Pathology and Medicine, Department of Pathology, University of California, San Diego, San Diego, CA, United States, 3Center for Veterinary Sciences and Comparative Medicine, University of California, San Diego, San Diego, CA, United States, 4Department of Medicine, School of Medicine and Chiba University–University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD), University of California, San Diego, San Diego, CA, United States, 5Future Medicine Education and Research Organization, Chiba University, Chiba, Japan, 6Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 7Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan, 8HanaVax Inc., Tokyo, Japan, 9Mucosal Immunology and Allergy Therapeutics, Institute for Global Prominent Research, Chiba University, Chiba, Japan, 10Research Institute of Disaster Medicine, Chiba University, Chiba, Japan, 11Institute for Advanced Academic Research, Chiba University, Chiba, Japan, 12Empowering Next Generation Allergist/Immunologist toward Global Excellence Task Force toward 2030 (ENGAGE)-Task Force, Tokyo, Japan

Mast cells (MCs) are immune cells widely distributed in the body, accompanied by diverse phenotypes and functions. Committed mast cell precursors (MCPs) leave the bone marrow and enter the blood circulation, homing to peripheral sites under the control of various molecules from different microenvironments, where they eventually differentiate and mature. Partly attributable to the unique maturation mechanism, MCs display high functional heterogeneity and potentially plastic phenotypes. High plasticity also means that MCs can exhibit different subtypes to cope with different microenvironments, which we call “the peripheral immune education system”. Under the peripheral immune education system, MCs showed a new character from previous cognition in some cases, namely regulation of allergy and inflammation. In this review, we focus on the mucosal tissues, such as the gastrointestinal tract, to gain insights into the mechanism underlying the migration of MCs to the gut or other organs and their heterogeneity, which is driven by different microenvironments. In particular, the immunosuppressive properties of MCs let us consider that positively utilizing MCs may be a new way to overcome inflammatory and allergic disorders.

KEYWORDS

mast cells, heterogeneity, inflammation, allergy, tolerance
Introduction

MCs predate the emergence of acquired immunity, since they were first named in 1878, a broad understanding of MCs biology has been published (1). Recently, an investigation of the hematopoietic origin of connective tissue MCs using fate-mapping systems has revealed the dual developmental origin of MCs (2). It was found that most connective tissue MCs (CTMCs) are derived from late erythro-myeloid progenitors (EMP) produced in the yolk sac at E8.5 (the second transient definitive wave of fetal hematopoiesis), while mucosal MCs (MMC) seem to come from hematopoietic stem cells (HSCs) in the bone marrow in mice (3). Committed progenitor cells enter the bloodstream, where they are found as lineage-negative Lin− c-Kit (CD117)+ FcεRi+ β7-integrinhi ST2+ CD16/32hi or FcεRi+ cells (4). In human beings, Lin− c-Kit+hi FcεRi+ β7-integrinhi CD34hi blood cells are considered the immediate precursor of MCs (5). These MCs travel in the blood circulation and eventually arrive at the peripheral tissues [e.g., skin, respiratory tract, urogenital tract, etc. (1)] under the stimulation and induction of various factors such as chemokine receptors and adhesion molecules. For example, in the context of microbiota-influence, MCs migrate to the intestinal tract and mature under the regulation of various pathways [e.g., α4β7-MAdCAM-1/VCAM-1 (6, 7), CXC chemokine receptor 2 (CXCR2) (7) sphingosine 1-phosphate (SIP) (8)].

In the process of migration and maturation, MCs of different origins showed distinct preferences in tissue localization (6). For instance, the adipose and pleural cavity MCs were derived from early EMPs, most of which were replaced by late EMPs during adulthood in mice (3). Late EMPs generate most of the MCs that home to connective tissues, while mucosal MCs mainly derive from fetal hematopoietic stem cells HSCs (3). Diverse tissue preferences also shape remarkable phenotypical and functional heterogeneity, suggesting that MCs may perform various functions in response to different physiological and pathological states (9).

Besides the developmental origin, differences in the tissue microenvironment are also important causes of MC heterogeneity (10). It is clear that MCs in different organs have noticeable differences (11). However, even in the same organ, the microenvironment under different pathological or physiological conditions can produce utterly distinct MC subtypes. Take some examples, in the lung, only MCs of the proximal lung express MRGPRX2, but not of the distal or medial lung (12); in the gut, both CTMCs and MMCs are present and can be transformed into each other in some cases, such as food allergy (13). All this evidence supports the remarkable microenvironment-dependent heterogeneity in MCs.

Different cellular phenotypes bring different functions—one of the representative features of the heterogeneity of MC is regulatory-like properties against inflammation and allergy. In some occasions, MCs have been shown to release cytokines to inhibit and terminate inflammatory and allergic responses (e.g., IL-2 (14) IL-10 (14–16), and TGF-β1 (17), etc.). In addition, MCs interact with regulatory T cells (Tregs) (14, 18–21) and alternatively activated macrophages (AAMφs) (22) to inhibit inflammatory and allergic responses.

In addition, various MC-derived cytokines [e.g., IL-4, IL-8, IL-13, IL-22, TNF-α, TGF-β1, vascular endothelial growth factor (VEGF), nerve growth factor (NGF), fibroblast growth factor-2 (FGF-2), and platelet-derived growth factor (PDGF)], proteases (trypsin and chymase/chymotrypsin), histamines, lipid mediators [PGD2 and leukotrienes (LTs), etc.] participate in the process of wound healing [e.g., vascular permeability and immune cells recruitment (monocytes and neutrophils), epithelial proliferation and migration, granular formation and remodeling, and scar formation, etc.] (11, 23).

Collectively, MCs play a diverse role in various physiological and pathological processes due to their highly complex heterogeneity. A full understanding of the phenotypic characteristics and functional heterogeneity of MCs in specific diseases will help us create efficient individualized therapy.

Aggregation of mast cells at intestinal mucosal sites

MCs exists in virtually all organs of vertebrates but different widely in their number, phenotype, and function (1). The high heterogeneity is partly attributed to their unique and complex maturation process. Although controversial (11), MCs are believed to have two main origins, bone marrow and yolk sac (2). After leaving the hematopoietic tissue, committed progenitor cells enter the blood, migrate, and colonize the target tissue [e.g., skin, respiratory tract, genitourinary tract, gastrointestinal tract, etc. (1)]. Notably, the exact ontogeny of adult MCs has been suggested in recent studies; early EMPs, late EMPs, and fetal HSCs are successively involved in the maturation of fetal MCs (2, 3). Using the inducible runt-related transcription factor 1 (Runx1-cre) and colony stimulatory factor 1 receptor (Csf1r-icre) fate-mapping systems, Zhiqing Li et al. separately traced three waves of hematopoiesis (3). They confirmed that late EMP-derived MCs, as long-lived cells, gradually replace early EMPs and become the main contributors to the adult CTMC pool. Early EMP-derived MCs show a short lifespan in connective tissue, only appearing in adipose tissue and the pleural cavity. Fetal HSC-derived MCs, another possible type of short-lived cells, are mainly located in mucosal tissues and constantly renewed by the bone marrow (3). Therefore, there are at least two ways that MCs mature in mice. However, whether these pathways apply to other mammals, including humans, is not fully understood.
After arriving in the peripheral tissues, MCPs finally differentiate into mature MCs with the stimulation of local cytokines and growth factors in humans (e.g., IL-4 (24), IL-9 (25), IL-33 (26, 27), and TGF-β1 (28), etc.) and mice (e.g., IL-3 (29), IL-4 (28), TGF-β1 (28), and NGF (30), etc.). However, unlike other granulocytic leukocytes (e.g., neutrophils, eosinophils, and basophils), MCs mature in peripheral sites rather than bone marrow. Consequently, there are very few MCPs or mature MCs in bone marrow and blood, so it is relatively difficult to evaluate human MCs. Moreover, the molecular expression necessary for MC migration varies not only during maturation, but also according to cellular characteristics, such as CMMCs or MMCs (31, 32). All of these make it relatively difficult to study human MCs in vitro. So far, MCs are studied mainly in rodents (e.g., genetically modified mice) or some malignant MCs cell lines (33, 34). We herein describe some mechanisms by which MCs migrate to the intestinal tract and mature in combination with current findings (Figure 1).

The intestinal mucosa, which is exposed to various foreign components (including microbiota and food components), is one of the primary destinations for MCs and the pool for MCPs (35). MCs have been reported to account for approximately 2% of the cells in the lamina propria of the gastrointestinal tract (36). There is no doubt that integrin α4β7 plays a critical role in the migration of MCs to the intestinal mucosa. MCPs is utterly absent in the small intestine of α4β7-deficient mice (6). Evidence suggests that integrin α4β7 interacts with vascular endothelial molecules, including mucosal addressing protein cell adhesion molecule-1 (MAdCAM-1) and vascular cell adhesion molecule-1 (VCAM1), to facilitate directional migration of MCPs across endothelial cells to the small intestine (6, 7).

![Assembly of MCs in the gut. The MCPs leave the hematopoietic tissue, enter the blood stream, migrate and colonize the target tissue. With c-kit, CXCR2, and integrin α4β7 on the cell surface, MCPs bind to MAdCAM-1 and VCAM1 on the vascular endothelial cells, thereby crossing the vascular endothelium and colonizing the intestinal mucosa and submucosa, where they mature. In addition, transcription factor (dendritic cell-derived T-bet), Lipid mediator (sphingosine 1-phosphate), and some intestinal microbiota affect the homing of MCs to the gut.](https://example.com/image.png)
Like all blood-borne leukocytes, adhesion interactions are not the only requirement for MCPs recruitment to peripheral tissues, but also the migration to target tissues. Stem cell factor (SCF) has chemotactic effects on both mouse (37) and human (38) MCs in vitro. In vivo, SCF activates the c-kit expressed by MCs (or MCPs) through PI3K, then mediates migration, survival, proliferation, and activation with the help of α4 integrin (39–42). No intestinal MCPs was detected in SCF-deficient mice (6).

CXCR2 also contributes to the migration of MCs. It was experimentally demonstrated that MCs lacking CXCR2 are less able to migrate to the small intestine (7). Although the research of the role of CXCR2 has not been extensively studied in other cells. For example, in rat cardiogenic endothelial cells, the binding of CXCR2 and its ligand CXCL5 leads to downstream PI3K activation and further cytokine production (43). Another study in which human CXCR2 was stably transfected into lymphoblastic JY cell lines showed that the activation of IL-8 (CXCR2 ligand) induced transient adhesion of α4β7 dependent on VCAM-1 (44). Consequently, it is reasonable to speculate that in the circulatory system, c-kit and CXCR2 expressed by MCPs can interact with their respective ligands to upregulate the affinity of α4β7 integrin with MAdCAM-1 and VCAM-1, and also enhance the expression of VCAM-1 on epithelial cells via PI3K pathway (45), which further promotes the migration of MCs (7).

Previous studies have indicated that gut microbiota can mediate the constitutive migration of MCs into the intestine (46). Germ-free (GF) mice showed a lower intestinal MC density and higher blood MCs density compared to SPF (specific pathogen free) mice, followed by an impaired intestinal MCs migration to the intestine. It remains to be seen whether intestinal bacteria directly or indirectly affect MC migration and maturation.

Interestingly, intestinal migration of MCs appears to be induced by a combination of gut bacteria, rather than a single bacterial strain. A study based on the Gram-positive Lactobacillus plantarum provided partial evidence that a single strain did not seem to mediate MC migration (47). Martin Schwarzer et al. found GF mice showed lower levels of CXCL1 and CXCL2 in the jejunal with fewer and less mature intestinal MCs in comparison to conventional mice after the induction of food allergy. In detail, the susceptibility to allergy symptoms in GF mice was fully restored after they were cohoused with conventional mice. However, similar results were not observed in mice mono-colonized with L. plantarum (47). L. plantarum was previously shown to aggravate allergic reactions associated with degranulation of MCs (48). Thus, it remains to be determined whether other single strains (e.g., Gram-negative bacteria) or specific bacterial products affect MC migration and maturation.

In addition, T-bet, a Th1-specific T-box transcription factor expressed by leukocytes [e.g., natural killer (NK) cells, dendritic cells (DCs), and CD8⁺ T cells], seems to mediate the migration of MCPs to the intestinal tract indirectly. Pilar Alcaide et al. found that T-bet⁻/⁻ mice showed lower number of MCPs homing to the small intestine or lungs (49). It is worth mentioning that T-bet expressing DCs somehow contribute to the migration of MCs since MC itself does not seem to express T-bet during development (49).

Moreover, our previous studies showed that S1P mediates the migration of MCs to the large intestine (8). S1P is a sphingolipid metabolite from platelets and MCs, which is thought to play a role in mediating the migration of lymphocytes from secondary lymphoid organs and the thymus (50). It has been know that MCs express various types of S1P receptors, including type I S1P receptor (SIP₁) (8), associated with G protein and small GTPases (e.g., Rho and Rac) (51, 52). By administration of FTY720 to mice, a blocker of SIP₁-mediated signaling, we found that FTY720 can directly inhibit the migration of MCs, demonstrating the requirement of SIP₁ signaling for MC migration (8).

Heterogeneity of mast cells and the peripheral education system according to the microenvironment

The unique maturation mechanism of MCs also contributes to their astonishing plasticity and heterogeneity, which fully reflects the complex interaction between MCs and microenvironmental signals transmitted by different tissues (10). Traditionally, MCs are classified according to the production of serine proteases, such as trypsin and chymase (11, 53). In mice, MCs are divided into MMCs and CTMCs (11, 53). MMCs, as the name implies, mainly exist in the mucosa (e.g., the intestinal mucosa) and express chymase mMCP-1 and mMCP-2. MMCs are the dominant phenotype in the mucosal layer, such as the gut (53). CTMCs can be found in connective tissue (e.g., intestinal submucosa, peritoneum, and skin) (1, 11, 54). CTMCs express chymase mMCP-4, trypsin (mMCP-6 and mMCP7), elastase (mMCP-5), and carboxypeptidase A3, etc. (1, 11, 54). Besides, the cytoplasm of CTMCs contains higher concentrations of heparin proteoglycan, histamine, and prostaglandin D2, while MMCs granules contain almost no heparin proteoglycan and lower levels of histamine (53, 55). Aside from the differences between the anatomic location and
protease composition, MMCs and CTMCs vary in the requirement of T cells-derived cytokines, IL-3, and IL-4 (56) (Figure 2). Similar to mouse MCs, human MCs can be divided into two types: one subtype secretes both tryptase, chymase and carboxypeptidase A3 (MC_{TC}); the other secretes tryptase alone (MC_{T}) (1). The former is similar to mouse CTMCs, while the latter is equivalent to MMCs. MC_{TC} is mainly distributed in the skin and small intestinal submucosa, and participates in pathological processes, such as urticaria (57). MC_{T} is mostly expressed in the lung and small intestinal mucosa and is related to asthma and food allergy (1). In the intestine, it is reported that MC_{T} accounts for approximately 98% of the total MC population in the mucus layer but only 13% of the total MC population in the intestinal submucosa (58), while MC_{TC} accounts for approximately 77% of the MC population in the submucosa (59). Another phenotype, MC_{C}, has also been mentioned in the intestinal mucosa (60). MC_{C} seems rich in chymase but deficient in tryptase (60). MC_{C} accounts for about 7% of the MCs in the intestinal mucosa and 17% in the intestinal submucosa (60); however, MC_{C} does not seem to be a unique population, given the small number of reports.

With the progression of research, it is currently considered that the existing MC classification system cannot distinguish the highly microenvironment-dependent MC heterogeneity (10, 54). For example, it has been revealed that CTMCs can express different protease phenotypes in different microenvironments within tissue locations in mice. CTMCs in trachea are mMCP-1, -2,-4 to 7, and CPA3, while those in skin and gut are only mMCP-4 to 7, and CPA3 (61). The ImmGen-project-derived microarray data also indicated that CTMCs subpopulations present more or less tissue-specific genetic programming differences in distinct anatomical locations, such as the skin, tongue, esophagus, trachea, and peritoneal cavity in mice (9). It has been reported that only 110 genes differentially expressed in tongue relative to trachea MCs and 122 in tongue relative to esophagus MCs. However, the difference in gene expression transcripts in peritoneal MCs relative tongue and skin MCs was 612 and 957, respectively (9). As a result, there is a growing call for a new classification method.

The plasticity of MCs in different environments has been well described. The most obvious evidence is that human MCs cultured from progenitor cells that obtained from different sites (e.g., peripheral blood, bone marrow, and cord blood) show significantly different in the expressions of receptors and granular components, and also differ in the response to the cytokines (33, 62, 63). In addition, according to the culture conditions by incubation with IL-1β, IL-4, IL-6, TGF-β1, and lipopolysaccharide in SCF-containing medium, human MCs change the protease expressions from trypsin to chymase (64, 65). In mouse MCs, co-culture with fibroblasts and stimulation with SCF induces the ability to synthesize and store heparin (66). Our previous study found that MCs co-cultured with intestinal-derived fibroblasts produce more heparin and MCPT1 and MCPT2 (10). Skin-derived fibroblasts, on the other hand, had quite different results (i.e., the increased expression of chondroitin sulfate and MCPT4 in MCs) (10, 67). According to our previous studies, there are significant differences between MCs in different organs or tissues. For example, intestinal MCs

**FIGURE 2**
Heterogeneity of MCs. MCs mature uniquely, developing them more susceptible to the tissue homeostasis of the peripheral tissue microenvironment, and thus exhibit different subtypes and secrete different mediators to achieve different functions.
expressed high levels of the extracellular ATP receptor P2X7, which mediates the activation of MCs and worsens intestinal inflammation. In contrast, skin MCs expressed lower levels of P2X7; importantly, once the expression of P2X7 is highly induced in skin MCs, chronic inflammation occurs (10, 68). With engaging, different tissue microenvironments can produce distinct MC subtypes, which seem to be required to maintain tissue homeostasis (11). Thus, it is worth mentioning that these series of terminal maturation of MCs may receive the effect of a "peripheral immune education system" dependent on the tissue microenvironment.

The gut serves as a vast repository of agranular Lin− c−Kit+ FceRlta− e4β7+ IL-33Rα+ FcyRIII/II+ MCPs (69, 70). The gut has almost 10 times more MCPs than the bone marrow in mice (71). With the constantly-changing microenvironment, the intestinal tract is likely to create a range of diverse MC phenotypes. For example, MCs differentiate in different pathological environments and obtain a more tissue- and disease- specific phenotype relative to health conditions, which shows their extreme plasticity. Nematodes, as one of the main drivers of intestinal MCs, not only mediate the migration and expansion of MCs (71), but also induce the change of MC phenotypes. Several studies based on the Trichinella spiralis helminth infection model have revealed that MCs have different phenotypes at different stages of the immune response. During nematode infection, MCs in the jejunal move from the submucosa to the epithelium and sequentially expressed mMCp-2, transiently expressed mMCp-9, stopped expressing mMCp-5 to -7, and finally expressed mMCp-1 (72–74). However, in the convalescent stage of infection, MCs returned to their original site and stopped expressing mMCp-1, mMCp-2, and mMCp-5 successively, accompanied by different expression combinations of mMCp-6, -7, and -9 (72–74). The parasite repelling effect of mMCp-1 has been proven (75). In conclusion, the plasticity of MCs has been fully demonstrated by their ability to migrate at different depths in intestinal tissue for the important host defense system.

In addition to parasitic infections, increased MCs in the intestinal mucosa have also been detected in IBD (15, 76), IBS (77, 78), and food allergy (13, 79, 80). In food allergy, inoculation of food antigens leads to a dramatic increase in MMCs (due partly to infiltrating MCPs and CTMCs). Induced by TGF-β1 (81) and the Notch signaling (13) in the inflamed intestine, precursor cells mature and even undergo a reciprocal transformation of CTMCs in the submucosa and/or MMCs in the mucosa, further demonstrating the environment-dependent heterogeneity of MCs (82). Additionally, Chen et al. identified a specific group of MMCs in food allergy named MMC9 (80). MMC9 cells are a group of MMCs of Lin− c−Kit+ FceRlta− β7− Integrinαvβ3 ST2+, which can secrete large amounts of IL-9 and IL-13. This population of cells develops from MCPs that migrate to the intestinal mucosa with the help of IL-4. Under the action of IL-3 and SCF, MMC9 has the potential to rapidly develops into granular MCs and drive IgE-mediated food allergy (80, 83).

Crosstalk between MCs and surrounding cells has been widely discussed, which significantly increased the complexity of the terminal differentiation of MCs. For example, studies showed intestinal neurons could be activated by the increased histamine and trypsin secreted from MCs enriched in IBS (77) and IBD gut (76). Correspondingly, intestinal neurons mediated MCs activation by secreting neuronal factors (e.g., substance P, somatostatin, ATP, neuropeptide corticotropin-releasing factor, etc.) that stimulate MC surface receptors (e.g., MRGPRX2, P2X7, etc.) (78). The activation of MCs and their pro-inflammatory and pro-allergic mechanisms were described in more detail elsewhere (11). In addition to intestinal neurons, MCs also crosstalk with other cell types such as Tregs and intestinal epithelial cells to show the identity transformation from pathogenic or allergenic to regulatory, which plays a pivotal role in the fight against allergic responses (14) and inflammation (84). The transformation of MCs from pathogenic to regulatory roles will be discussed in more detail in the next section.

Notably, with the continuous development of technology, more comprehensive methods have been used to detect the phenotypes of different MC populations, such as single-cell RNA sequencing (scRNA-seq). In mice, a study on hematopoietic stem and progenitor cells (HSPCs) in mouse bone marrow showed that E-cadherin could be expressed by early precursors of basophils and MCs, representing the commitment to the lineages (85). Notably, scRNA-seq based on the peritoneal cavity of mice may establish an entirely new developmental trajectory for MCs, given that a discrete group of cells called P1 was found under suitable in vitro culture conditions, which have the potential to differentiate into MCs and basophils (86). In human, a study based on scRNA-seq revealed MCs are existed in the human yolk sac. In these human yolk sac-derived MCs, hairy and enhancer of split 1 (HES1), nuclear receptor subfamily 4 group A member 2 (NR4A2), and Kruppel-like factor 1 (KLF1) were detected, which may have non-redundant effects on the differentiation and activation of MCs (87). Another origin of human MCs was also confirmed by scRNA-seq. The analysis of human cord blood identified a group of basophil/eosinophil/MCs progenitors, revealing a close link between MCs and erythroid commitment cells downstream from HSCs (88). In addition, an analysis of nasal polyps in the patients of chronic rhinosinusitis with nasal polyps detected an intermediate CD38hiCD117int MC phenotype distinct from circulating MCPs (12). The same study also confirmed that MRGPRX2 was expressed only in MCs of the proximal lung, but not in the distal or medial lung (12). A high ratio of tumor-suppressive TNF/vascular endothelial growth factor A (VEGFA) MC phenotype is found in nasopharyngeal cancer in the patients. It seems associated with a better prognosis (89), while another ground glass nodule adenocarcinoma analysis detected pro-inflammatory MGs (90). These results clearly indicated the origin- and microenvironment-dependent heterogeneity of MCs.
Deeper analysis of innovative techniques provide sufficient resolution to fully reveal the heterogeneity of MCs and show the differentiation trajectory and transcriptional heterogeneity of specific cell types in different tissues or disease settings, which helps identify novel putative immune cell subtypes (91).

**Mast cells act as the terminator of allergies and inflammation**

In pathological reactions, such as allergy and inflammation, MCs and their precursors can recruit and expand in the disease site. For example, Lin− c-Kitint/hi FcεRI+ CD34hi MCPs are recruited to peripheral tissues mediated by molecules [e.g., α4β7 integrins, VCAM-1 (92, 93)] and cells [e.g., CD11c+ cells (94), CD4+ cells (95)] in acute allergy. IgE (96) and its immune complexes (97) seem to be involved in the survival of MCs and the recruitment of MCPs. Consequently, MCs are closely involved in most allergy and inflammation processes.

Despite having outstanding achievements in innate and adaptive immunity, MCs have a well-deserved reputation as promoters of pathological actions, such as inflammation and allergy. However, as discussed previously, MCs’ distinctive migration and maturation patterns contribute to their remarkable plasticity and tissue-microenvironment-dependent heterogeneity. On this basis, we have reason to assume that MCs, as one of the most critical and primary immune cells in damaged tissues, may have positive regulatory functions in in vivo exacerbation and promotion of wound healing (111). Arginase-1 expressed by AAMΦs depletes the extracellular arginine necessary for T cell activation (112). Braune et al. and Fernando et al. found that IL-33 can induce IL-6 and IL-13 secretion by MCs through ST2, which plays a crucial role in AAMΦ polarization (111, 113). Consequently, IL-33 exerts immunosuppressive and anti-inflammatory effects by indirectly promoting AAMΦ polarization, thereby inhibiting the production of IL-17 and IFN-γ by T cells. Moreover, upon IL-33 stimulation, MCs secrete IL-10 and histamine to suppress LPS-mediated monocyte activation, which might be helpful against rheumatoid arthritis (114). Hence, it is plausible to believe that the IL-33/ST2-MC axis plays a positive role in limiting inflammation (115).

CD4+CD25+Foxp3+ Treg plays an essential role in immune tolerance. Several studies have shown intricate reciprocal crosstalk between MCs and Tregs. Experiments demonstrated that OX40 on the Treg surface could bind to OX40L expressed on the surface of MCs, subsequently inhibiting IgE-mediated MC degranulation (18). Moreover, TGF-β1 and IL-10 secreted by Tregs were thought to inhibit the expression of FcεRI on the MC surface, which also inhibit the MC degranulation (17, 78, 116). Notably, TGF-β1 reduced the expression of FcεRI subunit proteins α, β, and γ, while IL-10 inhibited only β proteins. TGF-β1 has also been reported to induce the apoptosis of MCs (108).

| TABLE 1 | The immunoregulatory effect of MCs. |
|---------|----------------------------------|
| **Mediators** (Secreted by MC) | **Mechanism** | **Reference** |
| IL-2 | Ensures the sustained and stable expression of Foxp3 in Tregs to maintain their development, proliferation, activity, and survival | (14, 98) |
| IL-10 | Inhibits the production of pro-inflammatory and pro-allergy cytokines (TNF-α, IFN-γ, IL-1, IL-13, and IL-6) | (99, 100) |
| | Inhibits the expression of FcεRI subunit protein β on MCs | (100) |
| | Inhibits the overactivation and over-proliferation of MCs and promotes MC apoptosis during stable and late inflammatory phases | (101–103) |
| | Inhibits the proliferation of T cells to inhibit inflammation | (104) |
| | Prevention of epithelial barrier dysfunction caused by IFN-γ and restoration of the epithelial barrier | (105) |
| | Inhibits adaptive immunity by suppressing the migration of mature DCs to the lymph nodes in the bladder | (106) |
| | Induces the production of Tregs and mediates autotoligenic tolerance | (20, 107) |
| Amphiregulin | Boosts the Treg function in colitis and tumors in the tumor-mediated intrinsic immunosuppression vaccination model | (21) |
| TGF-β1 | Inhibits the expression of FcεRI subunit proteins α, β, and γ on MCs and induces MC apoptosis | (8, 17, 108) |
| | Induces the production of Tregs and mediates autotoligenic tolerance | (20, 107) |
Research on allotransplantation in experimental mice showed that Treg-derived IL-9 could maintain the tolerance of allografts by affecting MCs (19). IL-9 is a critical factor in promoting the SCF-dependent growth, proliferation, recruitment, and activation of MCs (25), thus Treg-derived IL-9 and SCF synergistically activate hepatic MCs and promote the release of histamine, IL-2, and TGF-β1 in tolerogenic liver allografts. TGF-β1 promoted the generation of γδT cells, and IL-17 released by γδT cells further attracted Tregs and enhanced their immunosuppressive properties (117).

MCs also have inverse impacts on Tregs. MCs secrete TGF-β1, which contribute to Tregs production and mediate autoantigen tolerance (20, 107). Epidermal growth factor (EGF)-like growth factor amphiregulin, which MCs also secrete, directly boosted the Treg function in colitis and tumor vaccination models by activating the EGF receptor (EGFR) on them (21). EGFR is reported to mediate intrinsic immunosuppression in tumors, and EGFR-targeted therapies are widely used for tumors such as colorectal cancer (118) and non-small cell lung cancer (119). Therefore, the immunoregulatory mechanism of MCs may be further applied in tumor therapy.

MCs also seem to ensure the sustained and stable expression of Foxp3 in Treg cells by secreting IL-2, thus maintaining the development, proliferation, activity, and survival of Tregs at sites (98) to sustain their inhibitory function (120). Studies have shown that MC-derived IL-2 in the lung promotes Tregs proliferation and limits allergic airway inflammation (115). In addition, the feasibility of regulating food allergy by inducing Treg cells with a continuous exposure of low concentration of IL-2 has been demonstrated (79).

Our recent research revealed the role of MCs in the regulation of food allergies (14). To delve into the mechanism of a more effective treatment for food allergy, oral allergen desensitization-oral immunotherapy (OIT) from a mucosal immune system perspective, we established a clinically relevant murine model of OIT with an escalating oral dose of ovalbumin (OVA). The OIT protocol induced mucosal desensitized MCs in the intestinal compartment with a low degranulation capacity and IL-4 production but high IFN-γ production, which plays an indispensable role in allergy (14). IL-4 plays a key role in the initiation of food allergy to mediate the isotype switching of IgE, the food-specific-IgE generation from B cells, and the release of MC mediators (e.g., histamine) (121, 122). Moreover, Tomar et al. found that IL-4 promotes the development of MMC9 cells, partly through a basic leucine zipper ATF-like transcription factor-dependent pathway (83). Returning to our study, we detected a significant increase in Tregs from the mucosa, peripheral blood, and spleen in OIT treated mice group. In addition, we discovered that the dual synthesis of IL-2 and IL-10 by mucosal desensitized MCs induces Tregs and inhibits allergic symptom (14). In addition, OIT treatment induce desensitization to MCs and reduced their allergenicity by acquiring the regulatory function (Figure 3). It can be expected that elucidation of switch pathway of MCs from allergenic to regulatory properties can lead to the utilization of MCs in a positive manner to overcome the allergy.

IL-10 is a well-known anti-inflammatory cytokine that has been demonstrated to diminish the degree or duration of innate immune or acquired responses (123) by inhibiting the production of pro-inflammatory cytokines [TNF-α, IFN-γ, IL-1, and IL-6 (99)] and chemokines, and also the proliferation of T cells [e.g., CD4+ T cells (123) and CD8+ T cells (123, 124)]. It has been reported that MCs can reduce inflammation, tissue damage, leukocyte infiltration and restore the epithelial barrier function in an IL-10-dependent manner in multiple organs or tissues [e.g., gut (15) bladder (106) and skin (16)] and the antigen-specific T cell immune response caused by Anopheles mosquito saliva (125). MC deficiency can increase intestinal

**FIGURE 3**
Regulatory properties of MCs in the immunotherapy. OIT treatment for food allergy induces desensitization of MCs with the low expression of Th2 cytokines and increases expression of IFN-γ. Desensitized MCs also synthesize IL-2 and IL-10. MC-derived IL-2 and amphiregulin promote proliferation and enhancement of the function of Tregs. Activated Tregs release IL-10 and TGF-β1, and the OX40 on their surface binds to OX40L from MCs, which inhibits the expression of FccR1 on MCs and the release of TNF-α and IL-13, thereby inhibiting the Th2 responses.
permeability in IL10 knockout mice and cause spontaneous colitis (15). Artificial IL-10 supplementation prevented IFNγ-induced epithelial barrier dysfunction (105). In addition to the aforementioned Treg, MCs also secrete IL-10. Evidence of the secretion of IL-10 by MCs has been revealed both in vivo (14, 16) and in vitro (126). In Treg-independent graft-versus-host disease (GVHD), MCs have been found to show an immunosuppressive function by inhibiting T cell proliferation in an IL-10-dependent manner to inhibit inflammation (104). Although the mechanism through which MCs are triggered to produce IL-10 in the disease remains to be determined, it is speculated that endotoxin (LPS) from intestinal bacteria activates TLR4 in MCs, given that LPS has been shown to promote the production of Th2 cytokines by MCs (127). UVB promotes the production of MC-derived IL-10 by increasing the synthesis of vitamin D3 (128) to reduce allergic skin inflammation. Additionally, IL-10 derived from MCs, rather than Tregs, inhibits the migration of mature DCs to the lymph nodes in the bladder, which helps building the “immune privilege” (106).

In addition to their anti-inflammatory and allergic effects, MCs promote tissue repair and wound healing. Studies have shown that depletion of MCs partly inhibits wound healing (129). Furthermore, it has been revealed that IL-33/ST2 promoted the release of IL-13 and IL-22 from MCs (84). IL-13 signaling activates STAT6, which contributes to the survival and migration of epithelial cells and IL-22 can directly promote the production of mucus and the proliferation of epithelial cells (130, 131). Moreover, available evidence suggests that MCs are involved in almost all events of wound healing process (fibroblast migration/proliferation, and remodeling). In the early stage of wound formation, MCs are recruited to the injured site under the action of keratinocyte-derived IL-33, CCL2, and SCF; then they secrete various substances (23, 132). For example, MC produces TNF-α and stimulates DCs to express factor XIIIa, which promotes coagulation (23). Also, MC-derived histamine, lipid mediators [e.g., PGD2 and leukotrienes (LTs), etc.], and VEGF increase the vascular permeability to recruit monocytes and neutrophils (11, 23). Moreover, MCs are essential for the fibrotic process of wound healing. Proteases (e.g., tryptase and chymase), VEGF, IL-4, IL-8, NGF, FGF-2, PDGF, and TGF-β1, which are secreted by MCs, can contribute to angiogenesis, fibrin production, or re-epithelialization (23). At the end of wound healing, the proliferated blood vessels in the tissue degenerate, and the active granulation tissue is remodeled into fiber-rich scar tissue (133). Most studies agree that MCs are involved in this process (134), which might be mediated by gap-junctional intercellular communication between MCs and fibroblasts or myofibroblasts (135). In addition, MCs and zinc have been determined to induce the IL-6 production via Zn receptor GPR39 expressed on the cells in the inflammatory tissues such as fibroblasts, macrophages, and DCs (136). IL-6 is essential for wound healing (137).

In summary, although MCs show more inflammatory and allergic properties in the acute phase, they may exhibit more prominent functions during periods of inflammation or chronic inflammation subside to prevent excessive tissue damage and the development of chronic inflammation.

**Conclusion**

In general, MCs have high plasticity and tissue microenvironment-dependent heterogeneity owing to the distinctive migration and maturation modes. MCs interact with various cells at different physiological and pathological stages to exhibit vastly different functions. Comprehensively, understanding the heterogeneity of human MCs and determining their physiological functions under specific circumstances is a great challenge. Additionally, human MCs are difficult to obtain and isolate, and have poor ability to expand in vitro (63). Therefore, rodent MCs are widely used for the time being, which also gives rise to a new question: whether the results observed in these alternative models can be wholly inferred to human MCs. For example, human MCs and mouse MCs sometimes show different responses to the same cytokines or anti-allergic drugs (33, 138). Clinically, due to the profound negative impression that MCs promote inflammation and allergy, until recently, simply inhibiting MCs is still the mainstream way for clinical treatment of allergy and inflammation. Moreover, it is undeniable that MC neutralizing therapies do not seem to have satisfactory therapeutic effects due to the imperfect research at the present stage. According to this review, based on the strong microenvironment-dependent plasticity and heterogeneity of MCs, it appears promising to induce MCs to behave in a manner that regulates and inhibits chronic inflammatory and allergic responses. Accumulating research evidence might have revealed the great potential of MCs in treating disease by proper education in the peripheral tissues to terminate inflammation and allergy.

**Author contributions**

ZZ and YK conceived the idea for the review. ZZ and YK wrote the manuscript with constructive input from PE and HK. All authors read and approved the final version of the manuscript.

**Funding**

This work was supported by grants from The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) for LEADER; Japan Agency for Medical Research and Development (AMED) PRIME (20gm6010012h0004/20gm6210024h0001) and...
Project Focused on Developing Key Technology for Discovering and Manufacturing Drugs for Next-Generation Treatment and Diagnosis. The next-generation drug discovery and development technology on regulating intestinal microbiome (NeDDTrim) (JP21ae0121040); Japan Society for the Promotion of Science (JSPS) for Grant-in-Aid for Scientific Research S (18H05280) and Scientific Research B (19H03450), Challenging Research (Exploratory) 21K19494, Funds for the Promotion of Joint International Research (18KK0432), Future Medicine Funds at Chiba University, Danone Institute of Japan Foundation, The Naito Foundation, Hoyu Science Foundation, Waksman foundation of Japan, Yamada Science Foundation, The Institute of Medical Science, University of Tokyo (IMSUT) International Joint Research Project K003, and the Chiba University-UC San Diego Center for Mucosal Immunology, Allergy, and Vaccines (cMAV).

Acknowledgments

We thank Mr. Izumi Tanaka for the discussion. Figures were produced using Servier Medical Art (http://smart.servier.com/), licensed under a Creative Commons Attribution 3.0 Generic License (https://creativecommons.org/licenses/by/3.0/).

Conflict of interest

HK is director and founder of Hanayx Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Galli SJ, Gaudenzio N, Tsai M. Mast cells in inflammation and disease: Recent progress and ongoing concerns. Annu Rev Immunol (2020) 38:49–77. doi: 10.1146/annurev-immunol-071719-094903
2. Gentek R, Ghigo C, Hoefel G, Bulle MJ, Msallam R, Gautier G, et al. Hemogenic endothelial fate mapping reveals dual developmental origin of mast cells. Immunity (2018) 48(6):1160–71.e5. doi: 10.1016/j.immuni.2018.04.025
3. Li Z, Liu S, Xu J, Zhang X, Han D, Liu J, et al. Adult connective tissue-resident mast cells originate from late erythro-myeloid progenitors. Immunity (2018) 49(4):640–53.e5. doi: 10.1016/j.immuni.2018.09.023
4. Dahlin JS, Heyman B, Hallgren J. Committed mast cell progenitors in mouse blood differ in maturity between Th1 and Th2 strains. Allergy (2013) 68(10):1333–7. doi: 10.1111/all.12223
5. Dahlin JS, Malinovschi A, Ohvik H, Sandelin M, Janson C, Alving K, et al. Lin–CD34hi CD117int/hi FcepsilonRI+ cells in human blood constitute a rare population of mast cell progenitors. Blood (2016) 127(4):383–91. doi: 10.1182/blood-2015-06-650648
6. Gurish MF, Tao H, Abiona JP, Arya A, Friend DS, Parker CM, et al. Intestinal mast cell progenitors require CD48beta7 (alpha-betaz7 integrin) for tissue-specific homing. J Exp Med (2003) 194(9):1243–52. doi: 10.1084/jem.194.9.1243
7. Abiona JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA, Kuziel WA, et al. Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood (2005) 105(11):4308–13. doi: 10.1182/blood-2004-09-3578
8. Kurashima Y, Kunisawa J, Higuchi M, Uehara K, Takayama N, et al. Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy. J Immunol (2007) 179(3):1577–85. doi: 10.4049/jimmunol.179.3.1577
9. Dwyer DF, Barrett NA, Austen KF. Immunological Genome Project C. Expression profiling of constitutive mast cell progenitors reveals a unique identity within the immune system. Nat Immunol (2016) 17(7):878–87. doi: 10.1038/ni.3445
10. Kurashima Y, Amaya T, Fujisawa K, Shibata N, Suzuki Y, Kogure Y, et al. The enzyme CytoD mediates inhibition of mast cell activation by fibroblasts to maintain skin-barrier homeostasis. Immunity (2014) 40(4):530–41. doi: 10.1016/j.immuni.2014.01.014
11. Zhang Z, Kurashima Y. Two sides of the coin: Mast cells as a key regulator of allergy and Acute/Chronic inflammation. Cells (2021) 10(7):1615. doi: 10.3390/cells10071615
12. Dwyer DF, Ordovas-Montanes J, Albon SJ, Buchheit KM, Vukovic M, Derakhshan T, et al. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci Immunol (2021) 6(65):eabb7221. doi: 10.1126/sciimmunol.abb7221
13. Honjo A, Nakano N, Yamazaki S, Hara M, Uchida K, Kitaura J, et al. Pharmacologic inhibition of notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia. J Allergy Clin Immunol (2017) 139(3):987–96.e10. doi: 10.1016/j.jaci.2016.05.046
14. Takao T, Kurihara Y, Kiyuchi M, Hirahara K, Murasaki S, Arai F, et al. Orally desensitized mast cells form a regulatory network with treg cells for the control of food allergy. Mucosal Immunol (2021) 14(5):640–51. doi: 10.1038/s41385-020-00358-3
15. Chichlowski M, Westwood GS, Abraham SN, Hare LP. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS One (2010) 5(8):e12220. doi: 10.1371/journal.pone.0012220
16. Grimbaldeston MA, Nakae S, Kalenskoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet b. Nat Immunol (2007) 8(10):1095–104. doi: 10.1038/ni1503
17. Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, Wright HV, et al. TGF-beta 1 inhibits mast cell fc epsilon RI expression. J Immunol (2005) 174(10):5987–93. doi: 10.4049/jimmunol.174.10.5987
18. Gri G, Piconese S, Fossi B, Manfro V, Merluzzi S, Tripodo C, et al. CD4 +CD25 + regulatory T cells suppress mast cell degranulation and allergenic responses through OX40-OX40L interaction. Immunity (2008) 29(5):771–81. doi: 10.1016/j.immuni.2008.08.018
19. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Diabetes (2006) 442(7106):997–1002. doi: 10.2337/db06-0501
20. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 9(9):1202–8. doi: 10.1038/nm924
21. Zaaij DM, van Loonregt J, Gorlani A, Bekker CP, Groene A, Sibilia M, et al. Amphiregulin enhances regulatory T-cell suppressive function via the epidermal growth factor receptor. Immunity (2013) 38(2):275–84. doi: 10.1016/j.immuni.2012.09.023
cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during growth factor induces development of connective tissue-type mast cells. nprot.2006.344

Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate e proteoglycan. jem.174.1.7

Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood (1998) 91 (1) 187-95. doi:10.1182/blood.v91.1.187-187_195

Matsuzawa S, Sakashita K, Kinoshita T, To S, Yamashita T, Koji K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. j Immunol (2003) 170(7):3461-7. doi:10.4049/jimmunol.170.7.3461

Ikura M, Sato H, Kajiwara N, Oboki K, Ono T, Okumura Y, et al. IL-3 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest (2007) 87(10):971-8. doi:10.4161/labin.87.10.60663

Allakverdi Z, Smith DE, Comeau MR, Delepessle G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol (2007) 179(4):2057-8. doi:10.4049/jimmunol.179.4.2051

Macey MR, Sturgill JL, Morales JK, Falanga Y, Morales J, Norton SK, et al. IL-4 and TGF-beta 1 counterbalance one another while regulating mast cell homeostasis. J Immunol (2010) 184(9):4888-95. doi:10.4049/jimmunol.0903477

Razin E, Ehle JN, Selden D, Mencia-Huerta JM, Katz H, LeBlanc PA, et al. Interleukin-3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate e proteoglycan. j Immunol (1984) 132(3):1479-86.

Matsuda H, Kannan Y, Ushio H, Kiso Y, Kanemoto T, Suzuki H, et al. Nerve growth factor induces development of connective tissue-type mast cells in vitro from mouse bone marrow cells. j Exp Med (1991) 174(1):7-14. doi:10.1084/jem.174.1.7

Weller CL, Collington SJ, Brown JK, Miller HR, Al-Kashi A, Clark P, et al. Quantitative assessment of peripheral eosinophils and mast cells in inflammatory bowel disease. Histopathology (1996) 28(1):1-13. doi:10.1046/j.1365-2559.1996.263039.x

Saito H, Kato A, Matsumoto K, Okayama Y. Culture of human mast cells that mediate experimental autoimmune encephalomyelitis. J Immunol (1998) 160(11):5622-8. doi:10.4049/jimmunol.160.11.5622

Hallgren J, Jones TG, Abonia JP, Xing W, Humble M, Austen KE, et al. Pulmonary CXCXR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitors. Proc Natl Acad Sci U S A (2007) 104(15):20478-83. doi:10.1073/pnas.0709651104

Kuni J, Takahashi K, Kasakura K, Tsuda M, Nakano K, Hosono A, et al. Commensal bacteria promote migration of mast cells into the intestine. Immuno Вiology (2011) 216(6):692-7. doi:10.1016/j.immuni.2010.10.007

Schwarzer M, Hermanova P, Srtikova D, Golas J, Hudecovic T, Zwickers C, et al. Germ-free mice exhibit mast cells with impaired functionality and gut homing and do not develop food allergy. Front Immunol (2019) 10:2065. doi:10.3389/fimmu.2019.00205

Meijerink M, Wells JM, Taverne N, de Zeeuw Brouwer ML, Hilhorst B, Venema K, et al. Immunomodulatory effects of potential probiotics in a mouse peanut sensitization model. FEMS Immunol Med Microbiol (2012) 65(3):488-96. doi:10.1016/j.femsim.2010.10.007

Akade P, Jones TG, Lord GM, Gilcher LH, Hallgren J, Arinobu Y, et al. dendritic cell expression of the transcription factor T-bet regulates mast cell progenitor homing to mucosal tissue. J Exp Med (2007) 204(2):431-9. doi:10.1084/jem.20060626

Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol (2005) 23:127-59. doi:10.1146/annurev.immunol.23.021704.115628

Zhang et al. Skin microbiome promotes mast cell maturation by triggering stem cell factor. FEMS Immunol Med Microbiol (2011) 63(3):205-13. doi:10.1111/j.1574-6963.2010.01081.x

Lorentz A, Bischoff SC. Regulation of human intestinal mast cells by stem cell-derived mast cells (PSCMCs). J Immunol Methods (2017) 440:144-54. doi:10.1016/j.jim.2016.09.019

Frossi B, Mion F, Siblano R, Danelli L, Pucillo CEM. Is it time for a new classification of mast cells? what do we know about mast cell heterogeneity? Immunol Rev (2018) 282(1):35-46. doi:10.1111/imr.12636

Gurish MF, Austen KE. Developmental origin and functional specialization of mast cell subsets. Immunity (2012) 37(1):25-33. doi:10.1016/j.immuni.2012.07.003

Foord M, Fom E, Siblano R, Lazzari L, Pucillo CEM. Food allergy in adulthood and food allergy. Immunol Lett (2011) 137(1):43-9. doi:10.1016/j.imml.2011.05.005

Madden KB, Urban JFjr, Zilhenner HJ, Schrader JW, Finkelman FD, Katona IM. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol (1991) 147(4):1387-91.

Smith CH, Kepley C, Schwartz LB, Lee TH. Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol (1995) 96(3):360-4. doi:10.1016/0091-6749(95)90005-2

Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem (1998) 46(11):1509-15. doi:10.1177/1070291698046011

Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites. J Immunol (2005) 174(12):6955-60. doi:10.4049/jimmunol.174.12.6955

Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, et al. Interleukin-7: A growth factor for human mast cells. J Immunol (2006) 177(2):1009-17. doi:10.4049/jimmunol.177.2.1009

Kunisada S, Akashi T, Tsuda M, Ito H, Kuroda Y, et al. A novel method to generate and culture human mast cells. Periperal CD45+ stem-cell-derived mast cells (PSCMCs). J Immunol Methods (2014) 413:62-8. doi:10.1016/j.jim.2014.07.003

Eld I, Sabato V, van der Poorten MM, Faber M, Van Gasse AL, De Puyseleyt LP, et al. Peripheral blood cultured mast cells: Phenotype and functional outcomes of different culture protocols. J Immunol Methods (2021) 492:113003. doi:10.1016/j.jim.2021.113003
intermediaries in regulating IL-33/ST2 signaling for an immune network favorable

Zhang et al. 10.3389/fimmu.2022.937120

315(1):279-90. doi:10.1083/jcb.135.1.279

312(12):11408–13. doi:10.1038/jacs.2019.71

39(6):551-5. doi:10.1073/pnas.1908725116

45(3):1325–32. doi:10.1038/s41419-018-1223-4

2013(18):365–71. doi:10.1016/j.immuni.2012.10.019

56(11):e181078. doi:10.1126/sciimmunol.abo178

2019(574(7778)):365–71. doi:10.1038/s41586-019-1652-y

143(3):e8041. doi:10.1255/mdb.20178041

2009(31(2)):185–10. doi:10.1038/np059914012

135(1):279-90. doi:10.1083/jcb.135.1.279

182(4):2416–24. doi:10.1111/all.14633

1201200

2010(2):112–19. doi:10.1111/j.1365-2133.2009.03822.x

146(10):3444–51. doi:10.1182/blood-2010-07-286117

138(3):5251–60. doi:10.1172/JIMM.20191471

189(8):3869–77. doi:10.1073/pnas.1210213

145(13):1415–26. doi:10.1182/blood-2018-08-835355

108(5):1588–94. doi:10.1182/blood-2005-12-102781

13(4):478–502. doi:10.1038/jem.2011.84

180(7):4885–91. doi:10.1042/jem.2010187

15(3):216–21. doi:10.1023/B:LMIL.0000022165.05637

101(9):683–90. doi:10.1086/jcb.135.1.279

185(10):130–1. doi:10.1038/clintranslsci.2013.27

101(2):315–24. doi:10.1016/j.cccell.2017.12.004

189(17):6485–88. doi:10.1038/tpas.2013.175

180(7):4885–91. doi:10.1042/jem.2010187

18(3):5251–60. doi:10.1172/JIMM.20191471

186(8):3669–77. doi:10.1073/pnas.1210213

108(5):1588–94. doi:10.1182/blood-2005-12-102781

138(3):5251–60. doi:10.1172/JIMM.20191471

180(7):4885–91. doi:10.1042/jem.2010187

185(10):130–1. doi:10.1038/clintranslsci.2013.27

185(1):130–1. doi:10.1038/jem.2011.84

180(7):4885–91. doi:10.1042/jem.2010187

15(3):216–21. doi:10.1023/B:LMIL.0000022165.05637

185(1):130–1. doi:10.1038/jem.2011.84

185(1):130–1. doi:10.1038/jem.2011.84

15(3):216–21. doi:10.1023/B:LMIL.0000022165.05637

185(1):130–1. doi:10.1038/jem.2011.84

185(1):130–1. doi:10.1038/jem.2011.84

185(1):130–1. doi:10.1038/jem.2011.84
107. Zhao YB, Yang SH, Shen J, Deng K, Li Q, Wang Y, et al. Interaction between regulatory T cells and mast cells via IL-9 and TGF-beta production. Oncol Lett (2020) 20(6):360. doi: 10.3892/ol.2020.12224

108. Norozian F, Kashyap M, Ramireiz CD, Patel N, Kepley CL, Barstein BO, et al. TGF-beta1 induces mast cell apoptosis. Exp Hematol (2006) 34(5):579–87. doi: 10.1016/j.exphem.2006.02.003

109. Hart PH, Grimbaldston MA, Swift GJ, Jakic A, Noonan FP, Finlay-Jones JJ. Dermal mast cell determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice. J Exp Med (1998) 187(12):2045–53. doi: 10.1084/jem.187.12.2045

110. van der Pauw Kraan TC, Roeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med (1995) 181(2):775–9. doi: 10.1084/jem.181.2.775

111. Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One (2014) 9(4):e94188. doi: 10.1371/journal.pone.0094188

112. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, et al. Arginase-1 expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog (2019) 5(4):e1000371. doi: 10.1371/journal.ppat.1000371

113. Braune J, Weyer U, Hobusch C, Mauer J, Bruning JC, Bechmann I, et al. IL-10 inhibits fc epsilon RI expression in mouse mast cells. Frontiers in Immunology frontiersin.org 13

114. Morita H, Arae K, Unno H, Miyauchi K, Toyama S, Nambu A, et al. An inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. Proc Natl Acad Sci U S A (1995) 181(2):775–9. doi: 10.1084/jem.181.2.775

115. Gillespie SR, DeMartino RR, Zhu J, Chong HJ, Ramirez C, Shelburne CP, et al. Ability of interleukin-33- and immune complex-triggered activation of mast cell-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity (2015) 43(1):175–86. doi: 10.1016/j.immuni.2015.06.021

116. Gillespie SR, DeMartino RR, Zhu J, Chong HJ, Ramirez C, Shelburne CP, et al. IL-10 inhibits fc epsilon RI expression in mouse mast cells. J Immunol (2004) 172(5):3181–8. doi: 10.4049/jimmunol.172.5.3181

117. Nakano T, Lai CY, Goto S, Hsu LW, Kawamoto S, Ono K, et al. Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance. PLoS One (2012) 7(5):e37202. doi: 10.1371/journal.pone.0037202

118. Cunnigham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Metastatic colorectal cancer. J Clin Oncol (2015) 33(1):44–54. doi: 10.1200/JCO.2014.52.9457

119. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Flt3 ligand induces Th2 cell differentiation and proliferation in mature human mast cells. Proc Natl Acad Sci U S A (1999) 96(14):8080–5. doi: 10.1073/pnas.96.14.8080

120. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A (1999) 96(14):8080–5. doi: 10.1073/pnas.96.14.8080

121. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 19:683–765. doi: 10.1146/annurev.immunol.19.1.683

122. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol (1998) 160(7):3188–93.

123. Depinay N, Hacini J, Beghdadi W, Peronnet R, Machein S. Mast cell-dependent down-regulation of antigen-specific immune responses by mosquito bites. J Immunol (2006) 176(7):4141–6. doi: 10.4049/jimmunol.176.7.4141

124. Gali SJ, Kalensnikov J, Grimbaldston MA, Paliponsky AM, Williams CM, Tsai M. Mast cells as ‘unable’ effector and immunoregulatory cells: recent advances. Annu Rev Immunol (2005) 23:749–86. doi: 10.1146/annurev.immunol.23.100601.141025

125. Masada A, Yoshikai Y, Aiba K, Matsuuchi T. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-jun n-terminal kinase and p38 pathways. J Immunol (2002) 169(7):3801–10. doi: 10.4049/jimmunol.169.7.3801

126. Biggs I, Yu C, Fedorcik B, Lopez AF, Gali SJ, Grimbaldston MA. Evidence that vitamin D3 promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice. J Exp Med (2010) 207(3):455–63. doi: 10.1084/jem.20091725

127. Younan GJ, Heit YL, Daoiur P, Kekhua H, Xing W, Gurish MF, et al. Mast cells are required in the proliferation and remodeling phases of microenvironmental wound therapy. Plast Reconstr Surg (2011) 128(6):549–58e. doi: 10.1097/PRS.0b013e318230c55d

128. Brand S, Beigel F, Oslok T, Zitzmann K, Eichhorst ST, Otte JM, et al. IL-22 is increased in active crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol (2006) 290(4):G827–38. doi: 10.1152/ajpgi.00513.2005

129. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 112(6):334–44. doi: 10.1172/JCI33194

130. Trustmann A, Tokos A, Engelhardt B, Brocker ER, Gilitzir T. Mast cell involvement in normal human skin wound healing: expression of monococyte chemosattractant protein-1 is correlated with recruitment of mast cells which synthesise interleukin-4 in vivo. J Pathol (2000) 190(1):188–96. doi: 10.1002/(SICI)1096-9896(200001)190:1<188::AID-PATH496>3.0.CO;2-Q

131. Nishikori Y, Shiota N, Okunishi H. The role of mast cells in cutaneous wound healing in streptozotocin-induced diabetic mice. Arch Dermatol Res (2016) 308(9):823–35. doi: 10.1007/s00403-014-1496-0

132. Ud-Din S, Wilgus TA, Bayat A. Mast cells in skin scarring: A review of animal and human research. Front Immunol (2020) 11:552205. doi: 10.3389/fimmu.2020.552205

133. Moyer KE, Saggers GC, Ehrlip HP. Mast cells promote fibroblast repopulated collagen lattice contraction through gap junction intercellular communication. Wound Repair Regener (2004) 12(3):269–75. doi: 10.1111/j.1524-1558.2004.012310.x

134. Nishida K, Hasegawa A, Yamasaki S, Udchta R, Ohashi W, Kurashima Y, et al. Mast cells play role in wound healing through the Tz2/GpIpi3/Il-6 axis. Sci Rep (2019) 9(1):10842. doi: 10.1038/s41598-019-47132-5

135. Lin QZ, Kondo T, Ishida Y, Takayasu T, Mukaida N. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol (2003) 73(6):713–21. doi: 10.1189/jlb.0802397

136. Saito H, Hatake K, Dvorak AM, Leiferman KM, Donnenberg AD, Aran N, et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci U S A (1988) 85(7):2288–92. doi: 10.1073/pnas.85.7.2288